Canaccord analyst Kyle Mikson raised the firm’s price target on Guardant Health (GH) to $100 from $75 and keeps a Buy rating on the shares. The firm said their target increase is driven by increased revenue growth and operating margin expansion in the out years of our 10-year DCF model. Canaccord noted they reported 3Q25 results that were well ahead of firm estimates and FactSet consensus. Guardant’s performance was driven by broad-based growth in revenue and volume.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Reports Strong Q3 2025 Growth
- Guardant Health: Strong Performance and Growth Potential Drive Buy Rating
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings
- Guardant Health reports Q3 EPS (39c), consensus (49c)
- Guardant Health raises FY25 revenue view to $965M-$970M from $915M-$925M